Transparency, strength at the FDA

The Boston Globe, home town paper of  Senator Ted Kennedy, Chair of the Senate Health, Environment, Labor and Pensions Committee, ran two important commentaries on the FDA this week.

 First was an editorial  yesterday strongly urging Congress to pass a strong FDA reform bill, including restricting financial conflicts of interests for advisory committee members.

Today the Globe ran an oped coauthored by David Michaels and me, again calling for leaders in Congress to ensure that the final bill (it is now in "conference" between the House version and the Senate version) come out as strong  a bill as possible.

 Take a look, I hope the Senator does!

Susan Wood is Research Professor at George Washington University School of Public Health and Health Services, where she is part of the Project on Scientific Knowledge and Public Policy (SKAPP).

More like this

by Susan F. Wood Much has been written about the antibiotic drug, telithromycin, otherwise known as Ketek. It seems to combine a host of concerns all in one place (see also Matthews, AW, WSJ, May 19, 2006:B1). Critically, concerns about safety, from visual effects to fatal liver toxicity, are…
By Susan Wood Next week both the Senate and House are moving forward on legislation to reauthorize the Prescription Drug User Fee Act (PDUFA), along with other key FDA legislation.  The Senate will be âmarking upâ a large omnibus piece of legislation that combines PDUFA with drug safety…
 By Susan F. Wood, PhD  In an article in the New England Journal of Medicine today, Sheila Weiss Smith points out that the FDA has not been responsive to the Institute of Medicine (IOM) report on Drug Safety.  That study and its recommendations took on the question of how to improve our nation's…
 by Susan F. Wood, PhD On Wednesday Feb 21 at 3:00, the project on Scientific Knowledge and Public Policy at GWU School of Public Health and Health Services is hosting what hopefully will be a very exciting afternoon.  Former Commissioners of the FDA will gather to discuss the future of FDA,…